Related by context. Frequent words. (Click for all words.) 52 grade cervical lesions 52 follicular non 52 autoimmune inflammatory 51 cell malignancies 51 molecular assays 51 epothilone 51 molecular weight heparins 51 Aerosurf 50 Panzem R 50 nitric oxide donating 50 TYGACIL 50 Aloxi R 50 cell chronic lymphocytic 50 Homspera 50 concomitant medications 50 optical biosensors 49 photodynamic therapy PDT 49 Cereplast Hybrid Resins 49 polymerase inhibitors 49 therapeutic modalities 49 Azedra 49 Vfend 49 FavId 49 mixed dyslipidemia 49 Pegasys ® 49 chemotherapy induced neutropenia 49 ocular diseases 49 TELINTRA 49 liposomal formulation 49 ZYVOX 49 #:# STZ Wed 49 sunitinib malate 49 interferon alfa 49 parathyroid hormone PTH 49 refractory chronic lymphocytic 48 ZEGERID ® 48 SARMs 48 GAMMAGARD LIQUID 48 rheumatoid arthritis Crohn disease 48 subcutaneous formulation 48 Phase 2b clinical trials 48 coagulation factors 48 grade glioma 48 luteinizing hormone releasing 48 injection USP 48 Entereg R 48 proteins peptides 48 RH1 48 diabetes cardiovascular disease 48 Octreotide 48 dacetuzumab 48 angiotensin receptor blocker ARB 48 #:# STZ Mon 48 DAVANAT 48 calcineurin inhibitors 48 Carfilzomib 48 immunosuppressive agents 48 Rebif ® 48 hemostatic agent 48 hematologic malignancies 48 intravenous formulations 48 Targretin 48 investigational compounds 47 hematological malignancies 47 New Chemical Entities 47 rheumatoid arthritis psoriasis 47 Nanobody 47 Clonicel 47 dose methotrexate 47 amphotericin B 47 NXL# 47 immunomodulating 47 Traficet EN 47 Amplimexon 47 intravenous immunoglobulin 47 #:# ENC Fri 47 octreotide 47 inflammatory autoimmune 47 BioSilicon TM 47 #:# ENC Sat 47 Copegus R 47 topical steroid 47 Oncaspar 47 Clostridium difficile associated 47 Valsartan 47 chemical entities NCEs 47 sPLA2 47 voriconazole 47 primary hypercholesterolemia 47 ONTAK 47 immunologic diseases 47 cardiovascular metabolic 47 #:# TMC Tue 47 immunological diseases 47 non alcoholic steatohepatitis 47 dermatological diseases 47 immunomodulatory 47 opioid tolerant patients 47 myeloproliferative disorders 47 topical formulation 47 adecatumumab